ArticleHerz2026
Retrospective analysis of serum low-density lipoprotein cholesterol goal attainment and cardiovascular outcomes in coronary heart disease.
Article in Herz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to evaluate the association of low-density lipoprotein cholesterol (LDL-C) goal attainment and continuous LDL‑C levels with major adverse cardiovascular events (MACE) risk in real-world coronary heart disease (CHD) patients, and to support secondary prevention lipid management.
methodsThis single-center retrospective cohort study enrolled CHD patients at a tertiary hospital (2021-2024) with complete lipid and follow-up data. Baseline LDL‑C was recorded; patients were stratified by guideline-recommended targets based on cardiovascular risk (very high risk: < 1.4 mmol/L; others: < 1.8 mmol/L). Goal attainment was defined as baseline LDL‑C below the assigned target. The primary outcome was first MACE (cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or repeat revascularization). Median follow-up was 2.3 years. Kaplan-Meier, Cox regression (stepwise adjustment), propensity score matching, and restricted cubic splines were used.
resultsAmong 2476 patients (872 achievers, 1604 non-achievers), 382 MACE occurred. Achievers had significantly lower MACE incidence. Multivariable Cox regression showed goal attainment was associated with reduced MACE risk, an association that remained stable after adjusting for comorbidities, lipids, and therapy intensity. Propensity score matching confirmed the findings. Restricted cubic splines revealed a nonlinear dose-response relationship: MACE risk progressively increased with higher LDL‑C, especially at elevated concentrations.
conclusionIn real-world CHD patients, achieving guideline-recommended LDL‑C targets was significantly associated with lower MACE risk, with a nonlinear LDL-C-event relationship. The findings support intensive LDL‑C management in secondary prevention; however, the retrospective design limits conclusions about causality.
Indexed as
Identifiers
42484654What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.